Ask what the product actually is
FDA, the Food and Drug Administration, handles federal drug review. A peptide name on a page may be all that brought you to the offer. Ask what finished product is being proposed and how it would be used in the care plan. Keep the full answer, including whether it is described as approved or compounded. Do not fill in a missing detail from a different product with a similar name.
A peptide has a few parts linked together in a short chain; proteins contain the same kinds of parts. The name peptide did not prove FDA approval as of September 2026.
- What is the exact product?
- Is it an injection, a tablet, or another form of medicine?
- What is the proposed use for this injury concern?
Know what compounding means
Compounding means a licensed pharmacist or doctor prepares a medicine instead of supplying a drug company’s finished product. A business registered with FDA to prepare batches, called an outsourcing facility, can also do this work.
In September 2026, compounded drugs were outside FDA approval, with no agency verification of effectiveness, quality, or safety ahead of marketing.
FDA describes a role for compounding when a medical need cannot be met using an approved drug, or when that approved product is not commercially available.
Ask what need is being described in your case. The answer belongs with the actual preparation, the pharmacy, and the proposed follow-up. A broad statement about personalization does not tell you those details.
- What need is the preparation intended to meet?
- Why is an approved finished product not being proposed instead?
- Which pharmacy would prepare it?
Read BPC-157 and TB-500 claims with care
The FDA records searched in September 2026 contained no application for BPC-157 and therefore no approved U.S. product for it.
FDA lists safety concerns for BPC-157 and TB-500 on a page with an April 22, 2026 content date. TB-500 is a piece of another peptide, called thymosin beta-4. The page also says requests to consider these ingredients for compounding were withdrawn, or taken back.
Taking back those requests did not give either peptide FDA approval or add it to FDA’s list of ingredients for compounding.
In a draft policy published October 30, 2026, the U.S. Department of Health and Human Services (HHS) said its intent is to take no enforcement action against pharmacies and physicians with state licenses that meet all its conditions to compound BPC-157 alone or TB-500 alone for an individual patient’s prescription, never a blend; this is not FDA approval, and neither peptide is on FDA’s 503A bulks list.
Taking back a request does not tell you whether a treatment helps an injury. Keep the status claim separate from the evidence question, even when an offer combines them in a headline.
- What source is being used for the status claim?
- Does the source discuss the same ingredient and the same way of taking it, such as an injection or a tablet?
- What supports the specific recovery claim being made?
Treat research wording as a separate concern
The FDA letters checked in September 2026 alleged that products promoted for treating people were unapproved new drugs even when their labels used research wording.
Those letters concern particular sellers and are allegations, not court decisions. They do not turn a research label into a route to treatment. Ask about a clinical assessment and the actual product being offered rather than trying to turn research instructions into a care plan.
- Is the page discussing research or offering human treatment?
- Does it identify a health professional and an assessment?
- Is the product's status being stated clearly?
Ask what the study actually shows
Ask for the source behind the proposed use. Does it concern the same preparation, taken the same way, and the same problem? What outcome was examined? What uncertainty remains? This guide supplies no estimate of faster healing or a promised return to activity.
Keep the answer alongside the goal you brought to the assessment. The source guide collects the regulatory reading used here. The product concerns chapter covers quality questions and routes to help when a problem occurs.